Arabic Arabic English English French French German German
dark

Nestlé is set to acquire Aimmune in deal worth $2.6bn

Aimmune’s Palforzia therapy is the only FDA-approved peanut allergy drug

Read More

Total
0
Shares
Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

Tavanta Therapeutics, New Specialty Pharmaceutical Company, Has Diverse Pipeline of Novel Drugs and Risk-Balanced Approach to Product Development

Next Post

EU to contribute €400m to WHO’s COVID-19 vaccine facility

Related Posts
Total
0
Share